Skip to main content

Table 4 Clinical Outcome of study patients during in-hospital and 30-day follow-up based on MAGE levels

From: Effect of glycemic variability on short term prognosis in acute myocardial infarction subjects undergoing primary percutaneous coronary interventions

MAGE (mmol/L)

 

<2.37

2.37-3.65

>3.65

P

Subject number (n)

237

80

78

79

NA

Composite MACE

35 (14.8)

6 (7.5)

11 (14.1)

18 (22.8)

0.025

Cardiac death

4 (1.7)

1 (1.3)

1 (1.3)

2 (2.5)

0.775

Reinfarction

3 (1.3)

0 (0)

1 (1.3)

2 (2.5)

0.361

Repeated TVR

3 (1.3)

0 (0)

1 (1.3)

2 (2.5)

0.361

Recurrent angina

15 (6.3)

3 (3.8)

5 (6.4)

7 (8.9)

0.416

Malignant arrhythmia

10 (4.2)

2 (2.5)

3 (3.8)

5 (6.3)

0.477

Non-cardiac death

1 (0.4)

0 (0)

1 (1.3)

0 (0)

0.359

Non-IRA revascularization

53 (22.4)

12 (15)

16 (21)

25 (32)

0.037

  1. Data given as mean ± SD or n (%).
  2. MAGE, the mean amplitude of glycemic excursions; MACE, major adverse cardiac events; TVR, target vessel revascularization; IRA, infarct related arteries.